| 20 |
Xing Y, Chand G, Liu C, et al. Early phase I study of a (99m)Tc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer[J]. J Nucl Med, 2019, 60(9): 1213-1220.
|
| 1 |
Herbst RS, Garon EB, Kim DW, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study[J]. J Clin Oncol, 2020, 38(14): 1580-1590.
|
| 2 |
Mocan T, Sparchez Z, Craciun R, et al. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1(PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives[J]. Clin Transl Oncol, 2019, 21(6): 702-712.
|
| 3 |
Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies[J]. Lung Cancer, 2019, 135(1): 188-195.
|
| 4 |
Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641.
|
| 5 |
Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions[J]. Oncologist, 2019, 24(1): 31+41.
|
| 6 |
Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer[J]. Cancer Immunol Res, 2020, 8(1): 108-119.
|
| 7 |
Polverari G, Ceci F, Bertaglia V, et al. (18)F-FDG pet parameters and radiomics features analysis in advanced nsclc treated with immunotherapy as predictors of therapy response and survival[J]. Cancers (Basel), 2020, 12(5): 1163.
|
| 8 |
Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group[J]. Thorax, 2016, 71(2): 177-184.
|
| 9 |
冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[S]. 2009.
|
| 10 |
Akhurst T. Staging of non-small-cell lung cancer[J]. PET Clin, 2018, 13(1): 1-10.
|
| 11 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 12 |
陈燏，王玉秀，闵凌峰. NIX蛋白表达与非小细胞肺癌临床病理特征及预后[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 412-416.
|
| 13 |
梁任隆，彭小东，余倩如，等. 联合抗PD-1/PD-L1组合策略在肺癌治疗中的研究进展[J]. 中国老年学杂志，2020, 40(21): 4687-4691.
|
| 14 |
Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes[J]. Clin Cancer Res, 2019, 25(15): 4592-4602.
|
| 15 |
Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out[J]. Cancer Treat Rev, 2019, 75(1): 39-51.
|
| 16 |
Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9): 1441-1448.
|
| 17 |
Tsoukalas N, Kiakou M, Tsapakidis K, et al. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer[J]. J BUON, 2019, 24(3): 883-888.
|
| 18 |
Hepp T, Othman A, Liebgott A, et al. Effects of simulated dose variation on contrast-enhanced CT-based radiomic analysis for non-small cell lung cancer[J]. Eur J Radiol, 2020, 124(1): 108804.
|
| 19 |
Hughes DJ, Chand G, Goh V, et al. Inter- and intraobserver agreement of the quantitative assessment of [(99m)Tc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer[J]. EJNMMI Res, 2020, 10(1): 145.
|